                         SEQUENCE LISTING

<110>  AstraZeneca AB
 
<120>  Combination Treatments for Melanoma

<130>  201126-WO-PCT

<150>  US 63/208,728
<151>  2021-06-09

<150>  US 63/166,295
<151>  2021-03-26

<160>  16    

<170>  PatentIn version 3.5

<210>  1
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light chain variable domain of durvalumab

<400>  1

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser 
            20                  25                  30          


Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 
        35                  40                  45              


Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 
65                  70                  75                  80  


Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro 
                85                  90                  95      


Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105             


<210>  2
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy chain variable domain of durvalumab

<400>  2

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr 
            20                  25                  30          


Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu Ala Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  3
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDRH1 of durvalumab

<400>  3

Gly Phe Thr Phe Ser Arg Tyr Trp Met Ser 
1               5                   10  


<210>  4
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDRH2 of durvalumab

<400>  4

Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  5
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDRH3 of durvalumab

<400>  5

Glu Gly Gly Trp Phe Gly Glu Leu Ala Phe Asp Tyr 
1               5                   10          


<210>  6
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDRL1 of durvalumab

<400>  6

Arg Ala Ser Gln Arg Val Ser Ser Ser Tyr Leu Ala 
1               5                   10          


<210>  7
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDRL2 of durvalumab

<400>  7

Asp Ala Ser Ser Arg Ala Thr 
1               5           


<210>  8
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDRL3 of durvalumab

<400>  8

Gln Gln Tyr Gly Ser Leu Pro Trp Thr 
1               5                   


<210>  9
<211>  139
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light chain variable domain of tremelimumab

<400>  9

Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys 
1               5                   10                  15      


Arg Ala Ser Gln Ser Ile Asn Ser Tyr Leu Asp Trp Tyr Gln Gln Lys 
            20                  25                  30          


Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln 
        35                  40                  45              


Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe 
    50                  55                  60                  


Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr 
65                  70                  75                  80  


Cys Gln Gln Tyr Tyr Ser Thr Pro Phe Thr Phe Gly Pro Gly Thr Lys 
                85                  90                  95      


Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro 
            100                 105                 110         


Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu 
        115                 120                 125             


Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val 
    130                 135                 


<210>  10
<211>  167
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy chain variable domain of tremelimumab

<400>  10

Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser 
1               5                   10                  15      


Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro 
            20                  25                  30          


Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn 
        35                  40                  45              


Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp 
    50                  55                  60                  


Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu 
65                  70                  75                  80  


Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Arg Gly Ala Thr Leu 
                85                  90                  95      


Tyr Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val 
            100                 105                 110         


Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala 
        115                 120                 125             


Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu 
    130                 135                 140                 


Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly 
145                 150                 155                 160 


Ala Leu Thr Ser Gly Val His 
                165         


<210>  11
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDRH1 of tremelimumab

<400>  11

Gly Phe Thr Phe Ser Ser Tyr Gly Met His 
1               5                   10  


<210>  12
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDRH2 of tremelimumab

<400>  12

Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 
1               5                   10                  15  


<210>  13
<211>  24
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDRH3 of tremelimumab

<400>  13

Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Arg Gly Ala Thr Leu Tyr 
1               5                   10                  15      


Tyr Tyr Tyr Tyr Gly Met Asp Val 
            20                  


<210>  14
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDRL1 of tremelimumab

<400>  14

Arg Ala Ser Gln Ser Ile Asn Ser Tyr Leu Asp 
1               5                   10      


<210>  15
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDRL2 of tremelimumab

<400>  15

Ala Ala Ser Ser Leu Gln Ser 
1               5           


<210>  16
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDRL3 of tremelimumab

<400>  16

Gln Gln Tyr Tyr Ser Thr Pro Phe Thr 
1               5                   


